Free Trial
NASDAQ:GTBP

GT Biopharma (GTBP) Stock Price, News & Analysis

GT Biopharma logo
$2.94
-0.07 (-2.33%)
(As of 10/31/2024 ET)

About GT Biopharma Stock (NASDAQ:GTBP)

Key Stats

Today's Range
$2.86
$3.01
50-Day Range
$1.95
$3.30
52-Week Range
$1.92
$10.66
Volume
13,191 shs
Average Volume
425,299 shs
Market Capitalization
$4.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

GT Biopharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
10th Percentile Overall Score

GTBP MarketRank™: 

GT Biopharma scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Percentage of Shares Shorted

    0.53% of the float of GT Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    GT Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GT Biopharma has recently increased by 108.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    GT Biopharma does not currently pay a dividend.

  • Dividend Growth

    GT Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.53% of the float of GT Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    GT Biopharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GT Biopharma has recently increased by 108.00%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    GT Biopharma has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for GT Biopharma this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added GT Biopharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GT Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 10.00% of the stock of GT Biopharma is held by insiders.

  • Percentage Held by Institutions

    Only 8.15% of the stock of GT Biopharma is held by institutions.

  • Read more about GT Biopharma's insider trading history.
Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

GTBP Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines

GTBP Stock Analysis - Frequently Asked Questions

GT Biopharma's stock was trading at $7.65 at the beginning of the year. Since then, GTBP shares have decreased by 61.3% and is now trading at $2.96.
View the best growth stocks for 2024 here
.

GT Biopharma, Inc. (NASDAQ:GTBP) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($2.24) earnings per share for the quarter.

Shares of GT Biopharma reverse split on the morning of Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

GT Biopharma's top institutional investors include DekaBank Deutsche Girozentrale. Insiders that own company stock include Michael Martin Breen and Manu Ohri.
View institutional ownership trends
.

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

Last Earnings
8/14/2024
Today
10/31/2024
Next Earnings (Estimated)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GTBP
Previous Symbol
OTCMKTS:OXISD
Fax
N/A
Employees
8
Year Founded
1965

Profitability

Net Income
$-7,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.42 per share

Miscellaneous

Free Float
1,990,000
Market Cap
$4.15 million
Optionable
No Data
Beta
0.62

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:GTBP) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners